Select therapeutic use:

Bleeding disorders:

Indications for: NIPRIDE RTU

Induction and maintenance of controlled hypotension to reduce surgical bleeding.

Adults and Children:

Use infusion pump only. Monitor BP closely. Initially 0.3microgram/kg/min; may increase infusion rate every few minutes until desired effect; max 10microgram/kg/min. Renal impairment (eGFR <30mL/min/1.73m2): limit to <3microgram/kg/min. Anuric: limit to 1microgram/kg/min.

NIPRIDE RTU Contraindications:

Compensatory hypertension due to aortic coarctation or arteriovenous shunting. Inadequate cerebral circulation or moribund patients requiring emergency surgery. Congenital (Lebers) optic atrophy. Tobacco amblyopia. Acute HF associated with reduced peripheral vascular resistance. Concomitant sildenafil, tadalafil, vardenafil, or riociguat.

Boxed Warning:

Excessive hypotension. Cyanide toxicity.

NIPRIDE RTU Warnings/Precautions:

Use only when available equipment and personnel allow BP to be continuously monitored. Cyanide toxicity possible (esp. at infusion rates >2micrograms/kg/min); discontinue if develops; treat appropriately. Monitor plasma thiocyanate levels if cumulative dose >7mg/kg/day. Elevated intracranial pressure. Correct pre-existing anemia and hypovolemia, esp. during anesthesia. Hepatic impairment. Elderly. Pregnancy. Nursing mothers.

NIPRIDE RTU Classification:

Vasodilator.

NIPRIDE RTU Interactions:

See Contraindications. Hypotensive effect potentiated by ganglionic blocking agents and inhaled anesthetics.

Adverse Reactions:

Excessive hypotension, cyanide/thiocyanate toxicity, methemoglobinemia, anemia, hypovolemia.

Generic Drug Availability:

NO

How Supplied:

Single-dose vials (100mL)—1

CHF and arrhythmias:

Indications for: NIPRIDE RTU

Acute HF.

Adults and Children:

Use infusion pump only. Monitor BP closely. Initially 0.3microgram/kg/min; may increase infusion rate every few minutes until desired effect; max 10microgram/kg/min. Renal impairment (eGFR <30mL/min/1.73m2): limit to <3microgram/kg/min. Anuric: limit to 1microgram/kg/min.

NIPRIDE RTU Contraindications:

Compensatory hypertension due to aortic coarctation or arteriovenous shunting. Inadequate cerebral circulation or moribund patients requiring emergency surgery. Congenital (Lebers) optic atrophy. Tobacco amblyopia. Acute HF associated with reduced peripheral vascular resistance. Concomitant sildenafil, tadalafil, vardenafil, or riociguat.

Boxed Warning:

Excessive hypotension. Cyanide toxicity.

NIPRIDE RTU Warnings/Precautions:

Use only when available equipment and personnel allow BP to be continuously monitored. Cyanide toxicity possible (esp. at infusion rates >2micrograms/kg/min); discontinue if develops; treat appropriately. Monitor plasma thiocyanate levels if cumulative dose >7mg/kg/day. Elevated intracranial pressure. Correct pre-existing anemia and hypovolemia, esp. during anesthesia. Hepatic impairment. Elderly. Pregnancy. Nursing mothers.

NIPRIDE RTU Classification:

Vasodilator.

NIPRIDE RTU Interactions:

See Contraindications. Hypotensive effect potentiated by ganglionic blocking agents and inhaled anesthetics.

Adverse Reactions:

Excessive hypotension, cyanide/thiocyanate toxicity, methemoglobinemia, anemia, hypovolemia.

Generic Drug Availability:

NO

How Supplied:

Single-dose vials (100mL)—1

Hypertension:

Indications for: NIPRIDE RTU

Immediate reduction of blood pressure during hypertensive crises.

Adults and Children:

Use infusion pump only. Monitor BP closely. Initially 0.3microgram/kg/min; may increase infusion rate every few minutes until desired effect; max 10microgram/kg/min. Renal impairment (eGFR <30mL/min/1.73m2): limit to <3microgram/kg/min. Anuric: limit to 1microgram/kg/min.

NIPRIDE RTU Contraindications:

Compensatory hypertension due to aortic coarctation or arteriovenous shunting. Inadequate cerebral circulation or moribund patients requiring emergency surgery. Congenital (Lebers) optic atrophy. Tobacco amblyopia. Acute HF associated with reduced peripheral vascular resistance. Concomitant sildenafil, tadalafil, vardenafil, or riociguat.

Boxed Warning:

Excessive hypotension. Cyanide toxicity.

NIPRIDE RTU Warnings/Precautions:

Use only when available equipment and personnel allow BP to be continuously monitored. Cyanide toxicity possible (esp. at infusion rates >2micrograms/kg/min); discontinue if develops; treat appropriately. Monitor plasma thiocyanate levels if cumulative dose >7mg/kg/day. Elevated intracranial pressure. Correct pre-existing anemia and hypovolemia, esp. during anesthesia. Hepatic impairment. Elderly. Pregnancy. Nursing mothers.

NIPRIDE RTU Classification:

Vasodilator.

NIPRIDE RTU Interactions:

See Contraindications. Hypotensive effect potentiated by ganglionic blocking agents and inhaled anesthetics.

Adverse Reactions:

Excessive hypotension, cyanide/thiocyanate toxicity, methemoglobinemia, anemia, hypovolemia.

Generic Drug Availability:

NO

How Supplied:

Single-dose vials (100mL)—1